Another drug target we have identified for the treatment of breast cancer is peroxisome proliferator-activated receptor gamma (PPARG), a ligand-dependent transcription factor that is a member of the nuclear hormone receptor superfamily and plays an important role in regulating glucose and lipid metabolism in vivo. Here, PPARG is linked to breast cancer.